The BioPharm Brief: Bispecifics, Biocatalysis, and Dual-Pathway Therapies

Welcome to The BioPharm Brief, your daily snapshot of the biggest developments shaping biopharma and advanced therapeutics.

Today, we’re looking at three stories highlighting where innovation is accelerating across oncology, manufacturing science, and immunology.

First, Harbour BioMed has received FDA clearance to begin a Phase I clinical trial for HBM7004, a B7H4xCD3 bispecific antibody designed for advanced solid tumors. The investigational therapy works by redirecting T cells toward tumor cells expressing the B7H4 immune checkpoint protein. Bispecific antibodies continue to gain momentum in oncology because they can engage immune cells directly at the tumor site, potentially improving anti-cancer activity while reducing systemic toxicity. The company says preclinical studies showed encouraging anti-tumor activity and favorable safety signals.

Next, Merck published new research describing a scalable biocatalytic manufacturing process for enlicitide decanoate, its investigational oral PCSK9 inhibitor for lowering LDL cholesterol. Macrocyclic peptide therapies have historically faced manufacturing and scalability challenges, but Merck’s approach uses engineered enzymes and crystallization-based purification to improve efficiency. The work could have implications beyond cardiovascular disease, potentially supporting broader development of oral peptide therapeutics.

And finally, Johnson & Johnson released Phase 2b data for its investigational co-antibody therapy JNJ-4804 in refractory inflammatory bowel disease. The therapy simultaneously targets IL-23 and TNF-alpha, two major inflammatory pathways involved in ulcerative colitis and Crohn’s disease. Early data showed improved remission and endoscopic response rates in heavily treatment-experienced patients, reflecting growing industry interest in dual-pathway immune modulation strategies.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Summary of Key Developments

• Harbour BioMed advanced its B7H4xCD3 bispecific antibody into first-in-human clinical testing for solid tumors.
  
• Merck reported a scalable enzyme-enabled manufacturing process for oral macrocyclic peptide therapeutics
  
• Johnson & Johnson’s dual-pathway IBD therapy showed encouraging Phase 2b efficacy in refractory disease populations.